Corcept Therapeutics Incorporated(NasdaqCM:CORT) added to S&P 400
Corcept Therapeutics (CORT) has been added to the S&P 400 index. The company's stock has seen a 5-day change of -3.98%, a 1st Jan change of -2.22%, and a year-to-date increase of +216.93%.
How this was made
The 30-second read
Why it matters
The S&P 400 inclusion signals broader market acceptance and may trigger passive fund purchases.
Market read
Index addition is a modest catalyst for CORT and may benefit similar small‑cap biotech stocks.
What to watch
Potential dilution from increased float and higher scrutiny.
Background
Corcept Therapeutics (NasdaqCM:CORT) is a specialty pharmaceutical company focused on cortisol‑related therapies.
Ticker impact
Corcept Therapeutics was added to the S&P 400 index.
Potential modest upside as index funds add shares.
Historical data shows small-cap stocks often rally on index additions, but the move is typically limited.
Market effects
May lift other small-cap biotech stocks as investors rotate into the index.
U.S. small-cap market could see slight inflows.
Limited to U.S. equity markets.
Counterpoint
Index addition may be priced in quickly, limiting upside.
Key entities
- CompanyCorcept Therapeutics
Biotech firm added to S&P 400.
